Background: Protein tyrosine phosphatase 1B (PTPN1) dephosphorylates insulin receptors and attenuates insulin signaling. Polymorphisms in the coding sequence of PTPN1 have been variably associated with type 2 diabetes (T2D). We hypothesized that variations within the PTPN1 promoter might contribute to the development of T2D and related metabolic traits. Methods: We screened 2.0 kb of PTPN1 promoter in 174 T2D patients and 412 controls using PCR and denaturing HPLC. Association analysis was performed between diabetes and related traits and single-nucleotide polymorphism genotypes. We functionally tested 2 variants (؊1023C>A and ؊51delA) by measuring their influence on luciferase activity in HepG2 cells and performing the electrophoretic mobility shift assay (EMSA). Results: One common (؊1023C>A) and 6 rare (؊51delA, ؊451A>G, ؊467T>C, ؊1045G>A, ؊1286-3bp-del, and ؊1291-9bp-del) variants were identified in
tases are important regulators of insulin signal transduction. Recently, much attention has been directed toward protein tyrosine phosphatase, nonreceptor type 1 (PTPN1), 9 which negatively regulates the phosphorylation of insulin receptor and insulin receptor substrates (7, 8 ) .
Several studies investigated the association of PTPN1 single-nucleotide polymorphisms (SNPs) with traits related to T2D. Mok et al. (9 ) reported an association between an SNP in exon 8 and impaired glucose tolerance and T2D in Canadian aboriginal individuals. Similarly, Echwald et al. (10 ) observed an association of a coding SNP (P387L) with T2D in Danes. Di Paola et al. (11 ) identified a nucleotide insertion in the 3Ј untranslated region (UTR) that was associated with IR in obese individuals. Bento et al. (12 ) and Palmer et al. (13 ) investigated common variants in PTPN1 and found association with T2D and IR. Olivier et al. (14 ) observed a strong association between common haplotypes and hypertension, and also between individual SNPs and lipids and obesity, in Japanese and Chinese individuals. Florez et al. (15 ) studied 42 SNPs spanning 112 kb and selected partly from the HapMap Phase I database and partly from those previously studied but found no association between selected tag SNPs or haplotypes and T2D or diabetic phenotypes.
Human studies have demonstrated that PTPN1 expression increases in obese individuals and those with T2D (16, 17 ) . The effect of genetic variations on gene expression is one of the most likely mechanisms by which such variations can contribute to complex diseases such as T2D; obviously, gene promoter regions are the best targets to look for variations that affect gene expression and contribute to traits in health and disease. Few efforts have been made to identify variants within the PTPN1 promoter region and investigate their relationships with T2D and its related traits. In the present study, we hypothesized that variants in the PTPN1 promoter region not previously studied, identified, or well captured by variants available on HapMap Project Phase I (18 ) or in Phase II (release 19) at the r 2 ϭ 0.8 cutoff might affect T2D and related traits.
Patients and Methods study participants
We initially recruited 639 unrelated Iranian individuals ages 23 to 79 years. After excluding 43 individuals with abnormal glucose tolerance based on the WHO 1997 criteria (19 ) and 12 diabetic patients who were being treated with insulin, we performed genetic association analysis on 412 nondiabetic and 174 diabetic individuals. Written informed consent was obtained from all participants before enrollment in the study.
A detailed description of the study population has been published (20 ) . Screening included standardized questionnaires on personal data and clinical measurements such as age, sex, obesity, drug consumption during the past month, and medical or family history of diabetes. All those who were not taking diabetes medication underwent a 2-h oral glucose tolerance test (OGTT) after an overnight fast. Criteria for control selection was fasting glucose Ͻ6.1 mmol/L and 2-h plasma glucose Ͻ7.8 mmol/L after OGTT. Diabetes was defined as fasting glucose Ն7.0 mmol/L, 2-h glucose Ն11/1 mmol/L after OGTT, or use of hypoglycemic medication.
laboratory measurements
Blood samples were taken at 0 and 120 min. We measured glucose, total cholesterol, triglycerides, and HDL cholesterol using enzymatic methods on the Technicon ® analyzer RATM 1000 (Technicon Instruments). We measured serum concentrations of insulin by RIA (BioSource Europe).
classification criteria IR was assessed from glucose and insulin concentrations by use of the homeostasis model assessment of IR (HOMA-IR) equation (21 ) . Hypertension was defined as systolic blood pressure Ն85 mmHg, diastolic blood pressure Ն130 mmHg, or use of antihypertensive medication; parental history of diabetes was based on self-reported diabetes in one or both parents (22 ) .
variation detection
We screened variations by PCR and denaturing HPLC and confirmed them by direct sequencing. We used 8 sets of primers to amplify overlapping regions of the PTPN1 promoter from chromosome 20:48 558 283 to 48 560 496, corresponding to Ϫ2044 to ϩ169 of the transcription start site. Primer sequences and PCR conditions are listed in Table 1 . We performed initial screening on genomic DNA of 100 patients with T2D and 100 nondiabetic individuals (400 chromosomes in total) by denaturing HPLC using a Transgenomic WAVE HT DNA Fragment Analysis System (Transgenomic, Inc.). We confirmed all variants identified by denaturing HPLC by sequencing in both directions.
genotyping
We performed genotyping with either PCR-RFLP or denaturing HPLC. Genotyping of the Ϫ467TϾC variant was carried out by PCR amplification of a 269-bp segment using the following primers: forward, 5Ј-TTC ATT CCT GCA GCA CCC AAG-3Ј, and reverse, 5Ј-GTT GAG TCA CAG AGT GAG TGG-3Ј. The rare variant creates a restriction site (RS) for the AvaI enzyme, which cuts the PCR amplicon into 163 and 106 bp for a homozygous variant and 269, 163, and 106 bp for a heterozygote. For genotyping Ϫ1023CϾA SNP, genomic DNA was PCRamplified using the following primers: forward, 5Ј-TAG CAG AAA CCG AGT TTC ACC-3Ј, and reverse, 5Ј-CCT GGG TAA CAG AAT CAG ACC-3Ј. The SNP creates an RS for BclI, which cuts the 312-bp PCR amplicon into 249-and 63-bp fragments for variant homozygote. The Ϫ1045GϾA was genotyped with mismatch PCR-RFLP. Briefly, the PTPN1 promoter was amplified using a forward primer (5Ј-TCT GTT GAG ACC CTA ATG CCA GAA-3Ј) and a mutagenic reverse primer (5Ј-GGA TCA CCT GAG GTC AAG AGgC-3Ј). For the latter, a TϾG substitution was engineered at the penultimate primer base (shown above in lowercase). The presence of G at the variant position then created an artificial RS for BsuRI within the amplicon. The expected products after the digestion of the 268-bp amplicon with BsuRI were 268 bp for a wild-type homozygote; 245 and 23 bp for a variant homozygote; and 268, 245, and 23 bp for a heterozygote. Denaturing HPLC was used to genotype the Ϫ51delA, Ϫ451AϾG, 3-bp insertion-deletion, and 9-bp insertiondeletion variants. To identify the homozygotes for these polymorphisms, aliquots of a known wild-type sample were pooled with the unknown DNA samples before the reannealing step to enable heteroduplex formation before injection into denaturing HPLC.
genotyping of the Ϫ1023cϾa in hapmap samples
The Ϫ1023CϾA was genotyped in 90 HapMap Centre d'É tude du Polymorphisme Humain samples. We added the genotypes to those of HapMap samples (Phase II, release 19, 2005) for all markers in a 200-kb interval encompassing the PTPN1 gene. We used Haploview software (23 ) to produce the linkage disequilibrium (LD) structure.
cell culture
We obtained HepG2 cells from ATCC and cultured at 37°C under 5% CO 2 in DMEM (Gibco-BRL) supplemented with 10% fetal calf serum and 100 000 units/L penicillin/streptomycin.
transfection and luciferase reporter assay
We prepared 4 constructs from human genomic DNA obtained from participants with the Ϫ1023CϾA and Ϫ51delA genotypes. The oligonucleotides spanned the DNA sequence from Ϫ1100 (from the transcription start site) to ϩ169 bp for Ϫ1023CϾA and from Ϫ545 to ϩ169 bp for Ϫ51delA. We introduced the HindIII and XhoI sites at the ends of the PCR products that were cloned into the PGL3-Basic vector (Promega) after subcloning to the pcR2.1 TOPO. The sequences of the primers used are listed in Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem. org/content/vol53/issue9. We transiently transfected HepG2 cells with 1-g constructs using Fugene6. Ten hours after transfection, we treated the cells with 5.5 or 22.5 mmol/L glucose and 100 nmol/L insulin. Forty-eight hours posttransfection, we carried out the luciferase assay using the Dual-Luciferase Reporter Assay System (Promega). To control transfection efficiency, we mixed 0.25 g pRL-TK plasmid (Renilla luciferase under control of TK promoter; Promega) with experimental DNA. We performed parallel transfections with positive control vector (SV40-PGL3) and negative control vector (PGL3 with no insert). Firefly luciferase activity was normalized for Renilla luciferase activity. We repeated each transfection 6 times in triplicate, and data were averaged.
electrophoretic mobility shift assays
Synthesized wild-type and mutated oligonucleotides were 3Ј-end labeled with biotin-11-dUTP using the Biotin 3Ј-end DNA labeling reagent set (Pierce). The sequences of the used upper strands of the oligonucleotides are listed in Table 2 in the online Data Supplement. We performed electrophoretic mobility shift assays (EMSAs) by use of the LightShift Chemiluminescent EMSA reagent set (Pierce) on nuclear extract of HepG2 cells. For competition experiments, we added unlabeled wild-type, mutant, sterol regulatory element-binding protein (SREBP), Sp, and Egr1-consensus oligonucleotides in a 100-fold molar excess before the addition of the biotinylated probes.
statistical analysis
We performed statistical analysis by use of SAS (SAS Institute) and considered a 2-sided value of P Ͻ0.05 to be statistically significant. Baseline quantitative results are expressed as mean (SD). Concentrations of triglycerides, insulin, and HOMA-IR were log transformed. To determine the predictors of diabetes risk in this data set, we performed stepwise logistic regression analyses. We cal- 
Results

baseline characteristics of study samples
We included 586 Iranian individuals in the analyses of genetic association. All studied biomarkers significantly differed between the diabetic and the control groups (Table 2) .
genomic dna screening of the ptpn1 promoter Primary analysis of 2.0 kb of the PTPN1 promoter in 200 individuals revealed 7 variants: a deletion of A nucleotide at position Ϫ51 (Ϫ51delA), 4 SNPs (Ϫ451AϾG, Ϫ467TϾC, Ϫ1023-CϾA, and Ϫ1045GϾA), a 3-bp insertion-deletion (Ϫ1286 to Ϫ1288), and a 9-bp insertiondeletion (Ϫ1291 to Ϫ1299; Table 3 ). At the time of the present study, only Ϫ1023CϾA had been submitted to the public SNP database (http://www.ncbi.nlm.nih.gov/ SNP), corresponding to dbSNP entry rs6126029. Allele and genotype frequencies of each variant, as well as genomic position, are shown in Table 3 . None of the genotype frequencies significantly deviated from HardyWeinberg equilibrium. The frequency of the A allele of Ϫ1023CϾA SNP significantly differed between the T2D and nondiabetic individuals (P ϭ 0.020), whereas the difference in the genotype frequency between the 2 groups approached borderline significance (P ϭ 0.069; Table 3 ). None of the other markers was significantly associated with T2D.
To verify the association observed between the Ϫ1023CϾA variant and T2D, we performed stepwise logistic regression analysis, which included the genotypes of Ϫ1023CϾA variant, assuming an additive model along with established risk factors for T2D (Table 4) . Age, parental history of diabetes, HOMA-IR, smoking, and hypertension were the only significant predictors of T2D, suggesting that the Ϫ1023CϾA genotype is not an independent risk factor for T2D in this population.
power calculation
Considering the minor allele frequency (MAF) of the Ϫ1023CϾA and Ϫ51delA variants and 0.8 DЈ with the risk allele, and the ORs of 1.5 and 15% for frequency of the disease allele, our case-control provides 37% and 11% power, respectively, to detect associations between Ϫ1023CϾA and Ϫ51delA variants and T2D.
association analysis of ptpn1 promoter gene variants with biochemical and clinical phenotypes
We used a general linear model analysis to assess the relationship of genotypes of Ϫ1023CϾA and Ϫ51delA with biochemical and clinical features in the diabetic and Table 3 in the online Data Supplement). The Ϫ451AϾG variant is in complete LD with Ϫ467TϾC (r 2 ϭ 1.00). All other variants had low LD between each other.
To investigate whether Ϫ1023CϾA SNP was captured well by the previously studied SNPs, this variant was genotyped in the same 30 and other markers was 0.75 with rs6126033 (see Table 4 in the online Data Supplement).
effect of the Ϫ1023cϾa and Ϫ51delA polymorphisms on promoter activity
We used Genomatix to perform a bioinformatics search for potential binding sites for transcription factors at the sites of Ϫ1023CϾA and Ϫ51delA variations (http://www. genomatix.de/products/GEMSLauncher/GEMSLauncher2. html). The search identified potential binding sites for C2H2 zinc finger proteins, such as the specificity protein (SP) family and Egr1 at Ϫ51delA and SREBP at Ϫ1023CϾA. To validate these sites experimentally, we assessed the effect of the 2 variants on PTPN1 promoter activity by the luciferase reporter assay. As shown in Fig. 1 , there was no difference in luciferase activity between the 2 alleles of the Ϫ1023CϾA variant in the absence or presence of 5.5 or 22.5 mmol/L glucose and 100 nmol/L insulin. Constructs containing Ϫ51delA genotype showed 2-fold lower PTPN1 promoter activity compared with the wild-type construct in the absence or presence of 5.5 or 22.5 mmol/L glucose and 100 nmol/L insulin (P Ͻ0.001; Fig. 1 ).
determination of the binding of nuclear proteins by emsa
We performed EMSA to further verify the potential binding sites for transcription factors at Ϫ1023CϾA and Ϫ51delA variations. As shown in Fig. 1 in the online Data Supplement, 2 complexes, A and B, were retarded when the Ϫ1023C/A DNA fragments were used as probes. In unlabeled probe competition assays, excess of oligonucleotide A or C and SREBP consensus sequence eliminated the binding of complex B. The result suggests that a similar specific DNA-protein complex was formed with Clinical Chemistry 53, No. 9, 2007 both Ϫ1023C and Ϫ1023A. We also performed EMSA on nuclear extracts of HepG2 and labeled Ϫ51A, Ϫ51delA, Sp, and Egr1 probes. The results indicated that there are 3 complexes that specifically bind to the labeled probes. The 2 upper complexes correspond to the Sp consensus sequence, whereas the lower complex corresponds to the Egr1 consensus sequence (Fig. 2 ). Competition assay with unlabeled probes disrupted the binding of all labeled probes with nuclear proteins. As shown in Fig. 2A , the affinity of SP family proteins to the A allele was visibly higher than that to the delA (Fig. 2 , lane 7 vs lane 2).
Discussion
PTPN1 is a negative regulator of the insulin signaling pathway (16 ) . The importance of PTPN1 for several crucial metabolic pathways has been illustrated in mice deficient for this phosphatase (26 ) . These observations suggest that PTPN1 plays a role in attenuating insulin signal transduction. Variations in the PTPN1 promoter might affect gene regulation and could therefore be associated with T2D (7 ). Several studies have investigated the association of variants in the PTPN1 gene with T2D (9 -15, 27-31 ) , but none has included sequence analysis of the PTPN1 promoter region. Our study is the first to do so, and because we analyzed 400 chromosomes, we were able to identify variants even with low allele frequency. Both common and rare variants are expected to contribute to common diseases, as illustrated by the finding in the PCSK9 gene of a spectrum of alleles with a wide range of allele frequencies (0.2%-34%) associated with LDL cholesterol and magnitude of phenotypic effects (approximately 3% increase to 49% reduction in LDL cholesterol) (32 ) .
Identifying SNPs in the promoter region of the PTPN1 gene and testing their relations to T2D and its related traits is particularly important, because this region seems to be an SNP-poor area in the HapMap Project (Phase II, release 19) , for which the first available SNP (rs6020563) is Ͼ7 kb upstream exon 1 in PTPN1 gene. PCR-denaturing HPLC analysis of 2.0 kb spanning the PTPN1 promoter region identified 7 polymorphisms, which were then investigated in our entire sample. In the dbSNP genome EMSA was performed using Ϫ51A, Ϫ51delA, Sp, and Egr1 probes. Each binding reaction contained 3 g HepG2 nuclear extract and labeled Ϫ51delA (lanes 2-6), Ϫ51A (lanes 7-11), Sp (lanes 12 and 13), and Egr1 (lanes 14 and 15) oligonucleotides. Excess unlabeled Ϫ51delA (lanes 3 and 8), Ϫ51A (lanes 4 and 9), Sp (lanes 5, 10, and 13), and Egr1 (lanes 6, 11, and 15) oligonucleotides were included in the binding reactions as competitor. Lane 1 is negative control. Ϫ51A/delA oligonucleotides form 3 main gel retardation complexes corresponding to Sp and Egr1 family proteins. The affinity of SP family proteins to the A allele was significantly higher than that to the delA (lane 7 compared with lane 2). build 36.2, 7 SNPs were observed to map to the scanned area (see Table 5 in the online Data Supplement). None of these SNPs were detected in our scan. However, the sample size used to identify most of these SNPs was only 2, and the variation status for these SNPs is not verified, which casts doubts about their presence. Of the variants identified in our scan, only the Ϫ1023A allele seemed to be associated with a protective effect against T2D at P Ͻ0.05, but this association disappeared after adjusting for established T2D risk factors. An r 2 ϭ 0.8 cutoff was suggested to be able to capture both haplotype-and clade-specific patterns of variation (33 ) Given the low MAF of the Ϫ1023CϾA and Ϫ51Adel variants, we would have only 37% and 11% power, respectively, to detect association with T2D. Assuming ORs of the risk allele of 1.5 or 2.0 with 10% frequency and an 8% prevalence of T2D, we would need 2163 and 733 cases to detect association with the Ϫ51del variant, and 426 and 146 cases to detect association with the Ϫ1023 variant with 80% power at the Յ0.05 level. Table 6 in the online Data Supplement includes the number of samples needed to have 80% power to detect association with the Ϫ1023CϾA and Ϫ51delA variants at different ORs.
Our reporter assay studies showed no differences between Ϫ1023 C and A alleles on PTPN1 promoter activity in HepG2 cells. EMSA experiments suggest binding of the oligonucleotide that contains the Ϫ1023 variant alleles to SREBP in HepG2 cell nuclear extract. However, oligos that contain A or C alleles of this variant equally bind to SREBP. These observations suggest that the Ϫ1023CϾA variant has no functional role in T2D by modulating PTPN1 gene expression. In contrast, the Ϫ51delA genotype lowered the transcriptional activity in transient transfection experiments by 2-fold in comparison to the wild-type allele. This finding was confirmed by EMSA, in which Ϫ51A-containing oligonucleotide markedly bound more SP proteins than Ϫ51Adel (Fig. 2 , lane 7 vs lane 2), implying a lower affinity of Ϫ51delA allele to binding SPs.
Several studies reported association between variants in the PTPN1 and T2D or related traits in Hispanics (20 -26 ) , African Americans (34 ), or white twins (14 ) . However, Florez et al. (15 ) studied 42 SNPs in 7883 individuals and disclosed no association between individual SNPs and haplotypes with T2D. Because no variants in the promoter region of PTPN1 were available at the time when those studies were conducted, such SNPs could not be included upon selecting tag SNPs (Florez et al. (15 ) ); therefore, this method may have resulted in missing some variants that could or could not be associated with T2D.
We could not detect any influence of the Ϫ1023CϾA and Ϫ51delA variants on diabetes-related traits in the study groups. In fact, we observed a trend toward association between glucose and HOMA-IR levels and Ϫ51delA (P ϭ 0.09 and 0.10, respectively; data not shown). The reason that we observed an effect of the Ϫ51delA SNP on reporter gene expression but not on T2D-related traits might be a tissue-specific effect.
In conclusion, our study in a sample of Iranian T2D cases and controls identified several SNPs, of which the Ϫ1023CϾA SNP was the most frequent, but with no effect on PTPN1 expression or association with T2D and related metabolic traits after adjustment for established T2D risk factors. In addition, the rare Ϫ51delA variant significantly reduced the transcription of the luciferase reporter gene as well as the affinity to binding SP family proteins in HepG2 cells but had no significant physiological effect on T2D-related traits at P Ͻ0.05 in our sample. Ruling in or out a possible role of these 2 variants in T2D and related traits requires investigating them in a larger population. 
